ArticleFrontiers in genetics2026
Predictive value of peripheral blood cell-free DNA breast cancer gene mutation profiling for postoperative pathological malignancy in BI-RADS 4 breast nodules.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of peripheral blood cfDNA breast cancer gene mutation profiling for postoperative pathological malignancy in BI-RADS 4 breast nodules. Methods: Clinical data from 212 patients with BI-RADS 4 breast nodules at our hospital from January 2020 to January 2024 were retrospectively collected. Patients were divided into benign group (128 cases) and malignant group (84 cases) according to postoperative pathological results. Peripheral venous blood was collected within 1 week before surgery, cfDNA was extracted and targeted next-generation sequencing (NGS, coverage depth 500-1,000×) of 49 breast cancer-related genes was performed. cfDNA concentration, tumor mutation burden (TMB), mutation allele frequency (MAF), gene-specific mutation detection rates (BRCA1, TP53, ESR1, ERBB2, PIK3CA, Results: The malignant group had higher cfDNA concentration (14.3 ± 5.8 vs. 8.6 ± 3.2 ng/mL, P < 0.001) and TMB [2.86 (1.54,4.72) vs. 0.42 (0.28,0.68) mut/Mb, P < 0.001] than the benign group, while overall mutation detection rate (2.18% ± 0.63% vs. 2.84% ± 0.52%, P < 0.001), mutation coverage in promoter/regulatory regions of key driver genes (36.2 ± 9.5 vs. 45.6 ± 8.3 RPK, P < 0.001), and GMS (0.95 ± 0.74 vs. 1.82 ± 0.68, P < 0.001) were lower in the malignant group, indicating distinct mutation patterns. Mutation rates in BRCA1, TP53, ESR1, and ERBB2 in the malignant group were significantly higher than those in the benign group (P < 0.001). G3 grade patients had higher TMB and lower GMS, BRCA1/TP53 MAF, and regulatory region coverage than G1/G2 grade patients (P < 0.05). Multivariate logistic regression analysis showed that age (OR = 1.058, 95%CI: 1.021-1.096), BI-RADS classification (OR = 2.874, 95%CI: 1.643-5.027), TMB (OR = 4.326, 95%CI: 2.214-8.452), and GMS (OR = 0.178, 95%CI: 0.082-0.388) were independent predictors of postoperative pathological malignancy (P < 0.05). The combined model (age + BI-RADS classification + TMB + GMS) had an AUC of 0.923 (95%CI: 0.884-0.962), sensitivity of 88.1%, specificity of 89.1%, positive predictive value of 84.1%, and negative predictive value of 91.8%, superior to single indicators (P < 0.001). Conclusion: cfDNA breast cancer gene mutation profiling has good predictive value for postoperative pathological malignancy in BI-RADS 4 breast nodules, with TMB and GMS being independent predictors. The combined model integrating clinical, imaging, and gene mutation features demonstrates excellent predictive efficacy and can provide a non-invasive, accurate assessment tool for preoperative risk stratification of BI-RADS 4 lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.